You are here

linagliptin

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Pharmaceutical Business Review

Fri, 02/15/19 - 10:13 am

Boehringer Ingelheim

type 2 diabetes

clinical trials

Eli Lilly presents data from post-hoc analyses of linagliptin

Yahoo/Fly on the Wall

Tue, 09/24/13 - 10:09 am

Boehringer Ingelheim

New Diabetes Drugs May Push Eli Lilly Higher By 2013

Seeking Alpha

Thu, 06/21/12 - 07:39 am

Bristol-Myers Squibb

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions®

Yahoo/PR NewsWire

Sun, 06/10/12 - 11:10 am

type 2 diabetes

Boehringer Ingelheim

Eli Lilly announces Phase 3 study results for linagliptin

The Fly on the Wall

Thu, 05/24/12 - 10:01 am

Two-Year Data Comparing Cardiovascular Events with Linagliptin and the Sulfonylurea, Glimepiride, Presented as Late-Breaking Poster at ADA

Yahoo/PR NewsWire

Sat, 06/25/11 - 08:42 pm

Boehringer Ingelheim

New Phase III Data and Pooled Analysis for Linagliptin Show Improved Blood Sugar Control in Adults With Type 2 Diabetes When Used Alone and With Metformin

Yahoo/PR NewsWire

Sat, 06/25/11 - 12:03 pm

Boehringer Ingelheim

Federal court issues restraining order against Eli Lilly in federal lawsuit filed by Amylin

Yahoo/AP

Thu, 05/26/11 - 11:21 am

restraining order

Boehringer Ingelheim

Lilly, Boehringer Win FDA Approval for Type 2 Diabetes Drug

Bloomberg

Mon, 05/2/11 - 07:21 pm

type 2 diabetes

Boehringer Ingelheim

Boehringer Sees ‘Uphill Battle’ With Merck, Astra in Diabetes

Bloomberg

Mon, 10/5/09 - 10:33 am

Boehringer Ingelheim